NCT07743671 — Hereditary Hemorrhagic Telangiectasia trial site landscape

Public-registry site landscape for NCT07743671, “A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)”, a Hereditary Hemorrhagic Telangiectasia study sponsored by Vaderis Therapeutics AG. All data below is from public sources; Eichor is not affiliated with the sponsor.

Trial	NCT07743671 (registry record)
Study title	A Trial to Assess the Efficacy and Safety of Engasertib in Participants With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
Official title	A Phase 3, Randomized, Double-blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
Sponsor	Vaderis Therapeutics AG
Condition(s)	Hereditary Hemorrhagic Telangiectasia
Phase	PHASE3
Listed sites	0

Patient-friendly overview of this study: eichor.com/study/NCT07743671.

Free site-risk snapshot for this trial

Eichor generates a preliminary site-risk snapshot for NCT07743671 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →

Planning or rescuing a trial? Eichor generates evidence-linked site-risk reports from public data in minutes. Get a free preliminary snapshot →